Sunday, January 29, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Biodosimetry and Medical Countermeasures for Radiation Exposure

by Global Biodefense Staff
January 4, 2016
BAA Biodosimetry and Radiation Countermeasures

The federal government is accepting proposals to advance the development of candidate medical countermeasures (MCM) or biodosimetry biomarkers and devices to reduce health impacts of exposure to radiation.

Acts of radiological or nuclear terrorism could involve the use of stolen or improvised nuclear devices, attacks on nuclear power plants or reactors, the detonation of a dirty bomb, or the placement of radiation sources in public locations or in food or water supplies.

In addition, natural disasters like the 2011 earthquake and tsunami in Japan, resulting in radiation release from the Fukushima Daiichi Nuclear Power Plant, further emphasizes the need for radiological countermeasures.

Overseen by the National Institute of Allergy and Infectious Diseases (NIAID), the Broad Agency Announcement aims to move viable candidates toward eventual FDA approval or licensure to assess, mitigate or treat Acute Radiation Syndrome (ARS) and thereby improve survival.

Organizations selected under this BAA will have identified promising lead MCM candidates and have preliminary data demonstrating increased survival by mitigating or treating Acute Radiation Syndrome (ARS) in vivo in an appropriate animal model when first administered 24 hours or later after radiation exposure, or will have a promising biodosimetry biomarker/device demonstrating accurate radiation dose within ±0.5 Gy.

NIAID estimates that up to 4 contracts will be awarded for a 3-year period of performance beginning on or about December 1, 2016. The average cost per contract is $1-2 million per contract award per year.

Further details are available via Solicitation Number: BAA-NIAID-DAIT-NIHAI2015042. The proposal response deadline is March 22, 2016.

Tags: Animal ModelsBAABiodosimetryBiomarkers

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC